Caribou Biosciences, Inc. CRBU

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL -- -- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patient

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers -- -- ANTLER-3 pivotal phase 3 trial designed to address the unmet need in 2L LBCL patients at academic and community centers who lack treatment options with curative intent -- -- EHA oral presentation scheduled for Friday, June 12, 2026, at 5:15

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case study of a patient who previously received an anti-BCMA CAR-T showed an early complete response that was ongoing as of the data cutoff date -- -- EHA oral presentation scheduled for Sunday, June 14, 2026, at 11:00am CEST -- -- CaMMouflage phase 1 initial dose expansion data in BCMA-naïve and BCMA-expo

With a stock price of $2.36, Caribou Biosciences, Inc. (NASDAQ:CRBU) is among the 8 Best Up and Coming Penny Stocks to Buy Now. Caribou Biosciences, Inc. (NASDAQ:CRBU) attracted renewed attention after H.C. Wainwright analyst Robert Burns increased his price target on the stock to $11 from $9 on May 11 while maintaining a Buy rating following the […]

BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35pm ET in New York. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be availab

The market remained flat over the last week but is up 25% over the past year, with earnings forecast to grow by 17% annually. In light of these conditions, identifying stocks with strong financials and clear growth potential becomes crucial for investors seeking value. Although the term "penny stocks" may seem outdated, it still points to smaller or less-established companies that can offer significant opportunities; we've identified three such stocks that stand out for their financial...

BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou’s management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 12:30pm ET in New York, New York. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Carib

Celebrations may be in order for Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders, with the analysts delivering a...

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for oral presentations at the 2026 European Hematology Association (EHA) Annual Meeting, which will be held June 11-14, 2026, in Stockholm, Sweden. The first oral presentation will highlight the long-term durability of a single dose of vispa-cel in patients enrolled in the ANTLER pha

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +21.81% and -4.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?